Health Care • Biotechnology: Pharmaceutical Preparations
$3.19 ▼ -0.15
(-4.49%)
MKT CAP: $37.4M • VOL: 10.6K
52W L $2 52W H $10
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
NSRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.24B | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.9M | -$1.1M | -$1.1M |
| Operating Margin % | -0.4% | — | — |
| Net Income (GAAP) | -$5.9M | -$1.5M | -$1.1M |
| EBITDA (Normalized) | -$4.9M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.9M | -$665.0K | -$1.0M |
| Capital Expenditures (CapEx) | $14.0K | — | — |
| Free Cash Flow (FCF) | -$4.9M | -$665.0K | -$1.0M |
| FCF Margin % | -0.4% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.2M | $284.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.8M | -$3.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NSRX.